MSD's 45 Trillion Won Deal Falls Through... Big Pharma M&A Shifts from 'Pipeline' to 'Platform'
"Controlling the Value Chain Over a Single Blockbuster Drug"
"Platform and Vertical Integration Now Key Criteria for M&A"
As Merck & Co. (MSD) has suspended acquisition talks with oncology biotech company Revolution Medicines, attention is focusing on the reasons behind the decision. While it is reported that disagreements over the acquisition price were at the center of the issue, industry analysts say that big pharma's mergers and acquisitions (M&A) strategies are shifting from focusing on securing single blockbuster drugs to prioritizing the acquisition of platforms and production and supply chain capabilities.
According to foreign media reports on January 30, MSD was considering a deal worth around 40 trillion won for the acquisition of Revolution Medicines, but the two parties could not agree on the company's valuation. Revolution Medicines possesses RMC-6236 (daraksonrasib), an oral pan-RAS inhibitor candidate targeting pancreatic cancer and non-small cell lung cancer (NSCLC). Although it is a promising asset currently in Phase 3 clinical trials, its market capitalization has already approached 22.7 billion dollars (about 32 trillion won), and when factoring in a management control premium, the price became burdensome even for big pharma, which has been cited as the reason for the breakdown in negotiations.
The market does not interpret this case as a result of a lack of funds among large pharmaceutical companies. According to a recent report by global accounting and consulting group EY, last year the global life sciences M&A volume reached 240 billion dollars (about 342 trillion won), an 81% increase from the previous year's 130 billion dollars (about 185 trillion won). The average deal size also expanded by more than 80%. This indicates that global pharmaceutical companies facing the patent cliff still have significant capacity for large-scale acquisitions.
The market sees the standards for pharmaceutical M&As as changing. In a report published this month, global consulting firm Bain & Company analyzed that pharmaceutical companies' acquisition strategies are moving beyond simply securing blockbuster new drugs to acquiring platform technologies and control over manufacturing processes. The report stated, "Now, executives are asking themselves which parts of the value chain?from research and development to production and distribution?they need to own directly in order to gain a competitive edge," highlighting 'vertical integration,' which maximizes efficiency by internalizing the entire process from raw material procurement to finished product manufacturing, as this year's key trend.
Analysts believe that the breakdown in negotiations between MSD and Revolution Medicines is closely linked to this trend. Although Revolution Medicines has a promising late-stage clinical pipeline, there is a view that it may not have received high marks from MSD in terms of platform scalability?meaning the ability to apply its technology repeatedly to various diseases?or infrastructure to control the entire manufacturing process. For M&A deals involving tens of trillions of won, the key evaluation criterion is increasingly whether the target company possesses technologies, such as drug delivery systems or proprietary production platforms, that can be repeatedly applied to multiple pipelines, rather than just a single drug candidate.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Meanwhile, there are suggestions that for Korean biotech companies to gain a leading position in this year's global M&A market, they must take a strategic approach based on 'customized design' targeting big pharma. Joaquin Duato, Chairman of Johnson & Johnson, said at this year's JP Morgan Healthcare Conference, "Rather than simply favoring drugs at advanced clinical stages, platforms with clear alternative logic that can immediately strengthen our portfolio are the priority." Novartis CEO Vas Narasimhan also commented, "We are focusing on finding technology pieces?so-called 'bolt-on' assets?that can perfectly fit into the ecosystem we have built."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.